Venetoclax plus pediatric-inspired chemotherapy yielded an 87% post-induction response in adult T-ALL, with 75% MRD negativity among complete remissions and strong activity in ETP-ALL. Cytopenias were ...

At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push ...

The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. The combination of decitabine-cedazuridine ...

Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML. Just weeks after the FDA approved an all-oral ...

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires ...

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, explained how an all-oral AML regimen impacts infusion center logistics and patient visits. The May 2026 FDA approval of oral ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...

SEATTLE, WA / ACCESS Newswire / October 26, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today ...

The activity of six different genes can help determine survival in patients with acute myeloid leukemia (AML), according to a ...